Has Henry Osei, MD received payments from drug or device companies?

Yes. Drug and device makers reported $237 in general payments to Henry Osei, MD across 15 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Henry Osei, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Henry Osei, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Henry Osei, MD

Internal Medicine · Las Vegas, NVNPI 1235102716

Payments from drug & device makers

$237in general payments, 2019–2025

Across 15 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$78
AstraZeneca$32
Biohaven Pharmaceutical Holding Company Ltd.$30
Johnson & Johnson$28
Novartis$19
Amarin Pharma, Inc.$19
plus $32 from 2 others

What the payments were for

Food & beverage$237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	5	$78
AstraZeneca	2	$32
Biohaven Pharmaceutical Holding Company Ltd.	2	$30
Johnson & Johnson	2	$28
Novartis	1	$19
Amarin Pharma, Inc.	1	$19
Novo Nordisk	1	$17
Abbott	1	$15

How this compares

$237 in reported general payments places this provider in the 45th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada →

Medicare billing

Part B allowed, 2024

$52,113

Medicare patients

308

Services billed

494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	18	$21,673
Atorvastatin Calcium	127	$1,449
Tamsulosin Hcl	53	$1,052
Levothyroxine Sodium	103	$952
SynthroidLevothyroxine Sodium	21	$926
Rosuvastatin Calcium	51	$851
Omeprazole	47	$827
Losartan Potassium	65	$822
Amlodipine Besylate	119	$810
Celecoxib	13	$615
Gabapentin	35	$512
Potassium Chloride	30	$455
Pantoprazole Sodium	23	$435
Lisinopril	61	$431
Glipizide ErGlipizide	22	$374

Paid to pharmacies, not to this prescriber.

Other internal medicine in Las Vegas

Darin BrimhallLas Vegas$39.7M
Alton WaltersLas Vegas$8.9M
Michael JacobsLas Vegas$8.1M
Nirupa PaulrajLas Vegas$5.8M
Atoya AdamsLas Vegas$5.4M
Roger EstevezLas Vegas$3.7M
Syed PervaizLas Vegas$3.1M
Vrijendra HoonLas Vegas$1.8M
Robby Ann QuintosLas Vegas$1.4M
Kent SwaineLas Vegas$1.2M

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →